Nerviano Medical Sciences S.r.l. Announces Collaboration and Option to License Agreement with Merck

NERVIANO, 21 September 2022 Nerviano Medical Sciences S.r.l. (NMS), a member of the NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, announced today the signing of a collaboration agreement with licensing option with Merck Healthcare KGaA (Merck), for the next-generation highly selective and brain penetrant PARP1 […]
PROTAC (PROteolysis TArgeting Chimera)

Mirizzi D Chimica e Farmaceutica (2022), 6, 39-43
Molecular glues: un diverso approccio in drug discovery

Picconi P Chimica e Farmaceutica (2022), 6, 34-38
Prossimità chimicamente indotta

Mirizzi D Chimica e Farmaceutica (2022), 5, 48-52
Use of acridinium-based photocatalyst in the Giese-type coupling of arylboronic acids with electron poor olefins

Caldarelli M, Loriz L, Piazza L, Caputo G, DeAmici M, Papeo G Tetrahedron Letters (2022) 103, 153978
Stereoselective synthesis of 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as PIM kinase inhibitors inspired from marine alkaloids

Casuscelli F, Ardini E, Avanzi N, Badari A, Casale E, Disingrini T, Donati D, Ermoli A, Felder E, Galvani A, Isacchi A, Menichincheri M, Montemartini M, Orrenius C, Piutti C, Salom B, Papeo G Chirality (2022), 34(11), 1437-1452
BL-01, an Fc-bearing, tetravalent CD20 × CD5 bispecific antibody, redirects multiple immune cells to kill tumors in vitro and in vivo

Interdonato A, Choblet S, Sana M, Valgardsdottir R, Cribioli S, Alzani R, Roth M, Duonor-Cerutti M, Golay J Cytotherapy (2022), 24(2), 161-171
First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours

Schöffski P, Awada A, de la Bigne A, Felloussi Z, Burbridge M, Cantero F, Colombo R, Maruzzelli S, Ammattatelli K, de Jonge M, Aftimos P, Dumez H, Sleijfer S Eur J Cancer (2022), 169 (135-145)
Nerviano Medical Sciences S.r.l. Expands US Presence

Nerviano Medical Sciences S.r.l. (NMS Srl), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, announced today that it has expanded its presence in the US with the creation of a new US subsidiary, Nerviano Medical Sciences Inc. Nerviano Medical Sciences Inc. is incorporated […]
Nerviano Medical Sciences S.r.l. Announces First Patient Dosed in Phase 1 Clinical Trial of NMS-812 for The Treatment of Relapsed Refractory Multiple Myeloma (MM).

Nerviano Medical Sciences S.r.l., a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, recently announced that the first patient has been dosed in its Phase 1 clinical trial of NMS-812 in adult patients with relapsed refractory Multiple Myeloma (MM). NMS-812 is a novel potent […]